Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
J Endocrinol Invest ; 47(7): 1797-1803, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38227126

RESUMEN

PURPOSE: With the rise of medically assisted reproductive techniques (ART) the number of pregnancies complicated by gestational diabetes mellitus (GDM) has increased. The aim of this study was to evaluate retrospectively the outcomes of pregnancies complicated by GDM who conceive trough ART (cases) compared to those who conceived spontaneously (controls). METHODS: In 670 women with GDM, 229 cases and 441 controls, followed by the Diabetology of Padua, between 2010-2022, clinical-metabolic maternal characteristics and maternal-foetal outcomes were evaluated. RESULTS: As for the maternal clinical-metabolic characteristics, plasma glucose levels at 60' and 120' under oral glucose tolerance test (OGTT) at time of diagnosis were significantly higher in cases (177.4 ± 31.1 vs 170.9 ± 34.1 mg/dl, p = 0.016; 151.5 ± 32.2 vs 144.0 ± 33.4 mg/dl, p = 0.005 respectively). Furthermore, at diagnosis, cases show higher levels of total cholesterol (257 ± 53 mg/dl vs 246 ± 52 mg/dl; p = 0.012) and triglycerides (199.8 ± 83.2 mg/dl vs 184.9 ± 71.3 mg/dl; p = 0.02) compared to controls. As for maternal outcomes, thyroid disfunction, was recorded in a higher percentage in case (21.4% vs 14.3%; p = 0.008), as well as, the frequency of cesarean section (50.3% vs 41.2%; p = 0.038) and twin pregnancies (16.2% vs 2.5%; p < 0.001). As for neonatal outcomes, there were no statistically significant differences, except for the birth weight of the second twin, which was significantly lower in cases (2268 ± 536 vs 2822 ± 297 g; p = 0.002). No other significant differences were found. CONCLUSION: This study showed no meaningful differences in the outcomes of GDM pregnancies who were conceived with ART compared to that arose spontaneously as the patients were promptly diagnosed and treated.


Asunto(s)
Diabetes Gestacional , Resultado del Embarazo , Técnicas Reproductivas Asistidas , Humanos , Embarazo , Femenino , Diabetes Gestacional/diagnóstico , Diabetes Gestacional/epidemiología , Técnicas Reproductivas Asistidas/estadística & datos numéricos , Adulto , Resultado del Embarazo/epidemiología , Estudios Retrospectivos , Estudios de Casos y Controles , Prueba de Tolerancia a la Glucosa , Recién Nacido , Glucemia/análisis , Glucemia/metabolismo , Fertilización/fisiología
3.
Nutr Metab Cardiovasc Dis ; 25(4): 418-25, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25636381

RESUMEN

BACKGROUND AND AIMS: ApoA-I can undergo oxidative changes that reduce anti-atherogenic role of HDL. The aim of this study was to seek any significant differences in methionine sulfoxide (MetO) content in the ApoA-I of HDL isolated from young patients with coronary heart disease (CHD), type 2 diabetics and healthy subjects. METHODS AND RESULTS: We evaluated the lipid profile of 21 type 2 diabetic patients, 23 young patients with premature MI and 21 healthy volunteers; we determined in all patients the MetO content of ApoA-I in by MALDI/TOF/TOF technique. The typical MALDI spectra of the tryptic digest obtained from HDL plasma fractions all patients showed a relative abundance of peptides containing Met(112)O in ApoA-I in type 2 diabetic and CHD patients. This relative abundance is given as percentages of oxidized ApoA-I (OxApoA-I). OxApoA-I showed no significant correlations with lipoproteins in all patients studied, while a strong correlation emerged between the duration of diabetic disease and OxApoA-I levels in type 2 diabetic patients. CONCLUSIONS: The most remarkable finding of our study lies in the evidence it produced of an increased HDL oxidation in patients highly susceptible to CHD. Levels of MetO residues in plasma ApoA-I, measured using an accurate, specific method, should be investigated and considered in prospective future studies to assess their role in CHD.


Asunto(s)
HDL-Colesterol/sangre , Diabetes Mellitus Tipo 2/sangre , Infarto del Miocardio/sangre , Adulto , Apolipoproteína A-I/sangre , LDL-Colesterol/sangre , Estudios Transversales , Femenino , Voluntarios Sanos , Humanos , Masculino , Metionina/análogos & derivados , Metionina/metabolismo , Persona de Mediana Edad , Estrés Oxidativo , Factores de Riesgo , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción
4.
Nutr Metab Cardiovasc Dis ; 23(10): 913-9, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23786818

RESUMEN

AIMS: Advanced glycation end products (AGE) excess is one of the most important mechanisms involved in the pathophysiology of chronic diabetic complications. This review first summarizes the role of these compounds in microvascular pathogenesis, particularly in the light of recently proposed biochemical mechanisms for diabetic retinopathy, nephropathy and neuropathy. Then we focus on the relationship between AGE and metabolic memory, trying to clarify the former's role in the missing link between micro- and macrovascular complications. DATA SYNTHESIS: An excessive AGE formation has been demonstrated in the newly disclosed biochemical pathways involved in the microvascular pathobiology of type 2 diabetes, confirming the central role of AGE in the progression of diabetic neuropathy, retinopathy and nephropathy. As shown by recent studies, AGE seem to be not "actors", but "directors" of processes conducting to these complications, for at least two main reasons: first, AGE have several intra- and extracellular targets, so they can be seen as a "bridge" between intracellular and extracellular damage; secondly, whatever the level of hyperglycemia, AGE-related intracellular glycation of the mitochondrial respiratory chain proteins has been found to produce more reactive oxygen species, triggering a vicious cycle that amplifies AGE formation. This may help to explain the clinical link between micro- and macrovascular disease in diabetes, contributing to clarify the mechanisms behind metabolic memory. CONCLUSIONS: The pathophysiological cascades triggered by AGE have a dominant, hyperglycemia-independent role in the onset of the microvascular complications of diabetes. An effective approach to prevention and treatment must therefore focus not only on early glycemic control, but also on reducing factors related to oxidative stress, and the dietary intake of exogenous AGE in particular.


Asunto(s)
Diabetes Mellitus Tipo 2/complicaciones , Angiopatías Diabéticas/fisiopatología , Productos Finales de Glicación Avanzada/metabolismo , Microvasos/fisiopatología , Modelos Biológicos , Estrés Oxidativo , Animales , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/fisiopatología , Diabetes Mellitus Tipo 2/terapia , Nefropatías Diabéticas/metabolismo , Nefropatías Diabéticas/fisiopatología , Neuropatías Diabéticas/metabolismo , Neuropatías Diabéticas/fisiopatología , Retinopatía Diabética/metabolismo , Retinopatía Diabética/fisiopatología , Productos Finales de Glicación Avanzada/sangre , Humanos , Hiperglucemia/prevención & control , Microvasos/metabolismo
5.
J Matern Fetal Neonatal Med ; 35(25): 6021-6028, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33779467

RESUMEN

Women with GDM are at high risk of metabolic syndrome and type 2 diabetes (T2DM). A relationship with GDM and future development of cardiovascular disease (CVD) has been also recognized. Pregnancy and postpartum period in women with GDM give us the opportunity to identify the underlying, often unrecognized, CVD risk factors. Ideally, the postpartum follow-up of this women should be done by a multidisciplinary team to evaluate their cardio-metabolic risk and to counseling regarding lifestyle modification (healthy diet and regular physical activity) and breastfeeding that can reduce their risk. Longer follow-up of these women should be individualized, focusing attention on women at medium-high cardio-metabolic risk. The link between GDM and T2DM-CVD offers us a great opportunity for the diseases prevention.


Asunto(s)
Enfermedades Cardiovasculares , Diabetes Mellitus Tipo 2 , Diabetes Gestacional , Embarazo , Femenino , Humanos , Diabetes Gestacional/prevención & control , Diabetes Mellitus Tipo 2/prevención & control , Diabetes Mellitus Tipo 2/etiología , Periodo Posparto , Estilo de Vida , Enfermedades Cardiovasculares/prevención & control , Enfermedades Cardiovasculares/complicaciones
6.
Acta Diabetol ; 58(12): 1581-1585, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34181082

RESUMEN

AIM: The recent availability of vaccines against COVID-19 has sparked national and international debate on the feasibility of administering them to pregnant and lactating women, given that these vaccines have not been tested to assess their safety and efficacy in such women. As concerns the risks of COVID-induced disease, published data show that pregnant women who develop COVID-19 have fewer symptoms than patients who are not pregnant, but they are more likely to need hospitalization in intensive care, and neonatal morbidity. Aim of the present perspective paper is to analyze the current literature regarding the use of the vaccine against COVID-19 infection, in terms of safety and protection, in high risk pregnant women as those affected by diabetes and obesity. METHODS: Analysis of literature about vaccination against COVID-19 infection in pregnancy. RESULTS: The main health organizations and international scientific societies, emphasize that-although data regarding the use of COVID vaccines during pregnancy and lactation are still lacking-vaccination should not be contraindicated. It should be considered for pregnant women at high risk of exposure to COVID-19. For such women, the potential benefits and risks should be assessed by the healthcare professionals caring for them. A recent prospective study to test the immunogenicity and reactogenicity of vaccination with COVID-19 mRNA in pregnant and lactating women, has showed that SARS-CoV-2 mRNA vaccination triggers a robust humoral immunity in pregnant and lactating women; there was also evidence of an immune transfer to their newborn. CONCLUSIONS: We urgently need data on the effect of COVID-19 vaccination, in terms of maternal and fetal outcomes and vaccine related symptoms in high risk women during pregnancy and breastfeeding. It is important to run campaigns to promote vaccination, in particular in pregnant women at high risk to have severe COVID infection as those diabetics and/or obese.


Asunto(s)
COVID-19 , Diabetes Mellitus , Vacunas contra la COVID-19 , Femenino , Humanos , Recién Nacido , Lactancia , Obesidad , Embarazo , Mujeres Embarazadas , SARS-CoV-2 , Vacunación
8.
J Matern Fetal Neonatal Med ; 32(4): 687-694, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-28969466

RESUMEN

The prevalence of gestational diabetes mellitus is increasing, as is the worldwide prevalence of type 2 diabetes and obesity, even in children and adolescents. Exposure in utero to maternal diabetes carries several short-term consequences due mainly to maternal hyperglycemia, and consequent fetal hyperinsulinemia. Current evidence also supports the hypothesis that adult health and disease have developmental origins, and that disorders in early-life environments prompt metabolic imprinting that results in a greater risk of negative metabolic outcomes later in life. In particular, exposure in utero to maternal diabetes seems to influence long-term metabolic outcomes, carrying a higher risk of obesity and type 2 diabetes, and thus creating a vicious cycle for future generations. In this paper, the short- and long-term consequences of exposure in utero to hyperglycemia are reviewed, focusing particularly on the long-term metabolic consequences, and investigating the possible pathogenic mechanisms involved.


Asunto(s)
Diabetes Mellitus Tipo 1/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Gestacional/metabolismo , Obesidad/etiología , Efectos Tardíos de la Exposición Prenatal/metabolismo , Hiperinsulinismo Congénito/metabolismo , Diabetes Mellitus Tipo 1/etiología , Diabetes Mellitus Tipo 2/etiología , Femenino , Estudios de Seguimiento , Humanos , Hipoglucemia/metabolismo , Obesidad/metabolismo , Placenta/metabolismo , Embarazo , Factores de Riesgo
9.
Acta Diabetol ; 54(1): 45-51, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27638302

RESUMEN

AIMS: Analyze plasma phospholipid fatty acids (PPFA) composition and desaturase activity in women with gestational diabetes (GDM) and in women with a normal glucose tolerance (NGT) before and after delivery, and to evaluate the possible relationship between desaturase activity and inflammatory parameters. METHODS: PPFA composition was analyzed by gas chromatography in 21 women with GDM and from 21 with NGT, during the third trimester of pregnancy and 6 months after delivery. We used fatty acid product-to-precursor ratios to estimate desaturase activity, and we also measured in all women interleukins six and ten, tumor necrosis factor alpha and C-reactive protein. RESULTS: No significant differences were observed between NGT and GDM women in terms of PPFA composition, both in pregnancy and after pregnancy. Estimated desaturase Δ9-18 activity was significantly higher, and estimated desaturase Δ5 activity was significantly lower during pregnancy in all women. We observed no correlations between inflammatory markers and desaturases activity, during or after pregnancy, in both groups. CONCLUSIONS: Our data suggest that GDM does not influence PPFA composition and desaturase activity during pregnancy. In addition, late pregnancy characterized by hyperinsulinemia appears to upregulate desaturase Δ9-18 activity in NGT and GDM women.


Asunto(s)
Diabetes Gestacional/sangre , Ácido Graso Desaturasas/sangre , Ácidos Grasos/sangre , Fosfolípidos/sangre , Adulto , Proteína C-Reactiva , Colesterol/sangre , Citocinas/sangre , Registros de Dieta , Femenino , Prueba de Tolerancia a la Glucosa , Humanos , Inflamación/sangre , Embarazo , Tercer Trimestre del Embarazo
10.
Int J Endocrinol ; 2016: 2070926, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27956897

RESUMEN

The prevalence of gestational diabetes mellitus is increasing in parallel with the rising prevalence of type 2 diabetes and obesity around the world. Current evidence strongly suggests that women who have had gestational diabetes mellitus are at greater risk of cardiovascular disease later in life. Given the growing prevalence of gestational diabetes mellitus, it is important to identify appropriate reliable markers of cardiovascular disease and specific treatment strategies capable of containing obesity, diabetes, and metabolic syndrome in order to reduce the burden of cardiovascular disease in the women affected.

12.
Eur J Clin Nutr ; 63(10): 1269-71, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19623196

RESUMEN

We examined the effects of 2 months of psyllium treatment in optimizing metabolic control and lipoprotein profile, and its postprandial effects on lipids in type II diabetes. We recruited 40 type II diabetic patients who were on sulfonylureas and a controlled diet, sequentially assigning them to psyllium treatment (G1) or to a control group (G2) treated with dietary measures alone. After 2 months of treatment, body mass index, waist circumference, HbA1c (hemoglobin A1c) and fasting plasma glucose levels had significantly decreased in both groups. There were no postprandial differences in the lipoprotein profile between the two groups. Triglycerides were significantly lower in G1, but not in G2. Our study contributes toward elucidating the effects of psyllium on serum lipids, and suggests that psyllium treatment may help in reducing triglycerides (a known risk factor for cardiovascular disease) in type II diabetic patients.


Asunto(s)
Catárticos/farmacología , Diabetes Mellitus Tipo 2/sangre , Hipertrigliceridemia/tratamiento farmacológico , Fitoterapia , Psyllium/uso terapéutico , Triglicéridos/sangre , Glucemia/análisis , Glucemia/metabolismo , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Femenino , Hemoglobina Glucada/análisis , Humanos , Hipertrigliceridemia/sangre , Masculino , Persona de Mediana Edad , Periodo Posprandial , Psyllium/farmacología , Pérdida de Peso/efectos de los fármacos , Pérdida de Peso/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA